As India’s healthcare landscape evolves with cutting-edge diagnostic solutions, Chennai is set to witness a transformative development in Alzheimer’s screening. The Mispa i60, introduced at Neuberg Diagnostics, Chennai, offers a simple blood test to detect early signs of Alzheimer’s disease using only a blood sample, making it a non-invasive and cost-effective screening option. This test serves as an adjunct to clinical evaluation and does not replace neuroimaging or cerebrospinal fluid (CSF) testing.
This technology leverages p-tau and amyloid proteins, which are strongly associated with Alzheimer’s disease, enabling the detection of early pathological changes well before noticeable cognitive decline begins.
Early identification can significantly enhance treatment planning and help clinicians distinguish Alzheimer’s disease from other forms of dementia that present with similar symptoms.
“Alzheimer's disease shares overlapping clinical features with other types of dementia, making diagnosis challenging. Studies have shown that a proportion of clinically diagnosed Alzheimer’s cases reveal non-Alzheimer’s pathology upon autopsy, further emphasizing the importance of accurate biomarker testing,” says Dr Asma Bibi, Chief of Laboratory, Neuberg Diagnostics. “This blood test can help differentiate Alzheimer’s from other dementia syndromes, ensuring that patients receive the correct diagnosis and appropriate treatment. We are excited about the possibilities this test brings for both clinicians and patients.”
Among patients who underwent this test at Neuberg’s OMR centre in Chennai, 45% were found to have an elevated tau-to-amyloid ratio, suggestive of underlying Alzheimer’s pathology. These findings were further supported through neurologist assessment and clinical evaluation. This outcome highlights the test's high concordance with traditional diagnostic methods while offering a faster and non-invasive alternative.
With Alzheimer’s disease affecting a significant proportion of the global population, early detection is critical for effective treatment and management. Innovations like these are poised to bring more timely and accurate Alzheimer’s screening to both urban and regional settings, enabling early intervention for patients across Tamil Nadu.
